Back to the Top
The following message was posted to: PharmPK
Hi
If we include female subjects for first time in phase
I study, assume no genotoxicity, our concern is the
DDI of test compound and contraceptive drug. Could any
certain hormonal contraceptive drug be safer if the
test compound is a broad spectrum antibiotic,
metabolized by CYP3A4 mainly and CYP1A2 minor, low to
moderate inhibition to CYP1A2 and low to moderate
induction to CYP1A2.
Thanks for your help
Lisa
Back to the Top
The following message was posted to: PharmPK
I think you could use the patch which doesn't depend on enterohepatic
recycling of estrogen.
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "DDI with hormonal Contraceptive" as the subject | Support PharmPK by using the |
Copyright 1995-2011 David W. A. Bourne (david@boomer.org)